4D Molecular Therapeutics (FDMT) Asset Utilization Ratio (2021 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Asset Utilization Ratio for 5 consecutive years, with 0.0 as the latest value for Q3 2025.
- On a quarterly basis, Asset Utilization Ratio rose 862.66% to 0.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.0, a 862.66% increase, with the full-year FY2024 number at 0.0, down 99.88% from a year prior.
- Asset Utilization Ratio was 0.0 for Q3 2025 at 4D Molecular Therapeutics, up from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.09 in Q2 2021 to a low of 0.0 in Q3 2024.
- A 5-year average of 0.03 and a median of 0.01 in 2022 define the central range for Asset Utilization Ratio.
- Peak YoY movement for Asset Utilization Ratio: tumbled 99.95% in 2024, then skyrocketed 862.66% in 2025.
- 4D Molecular Therapeutics' Asset Utilization Ratio stood at 0.06 in 2021, then plummeted by 80.99% to 0.01 in 2022, then soared by 411.69% to 0.06 in 2023, then tumbled by 99.89% to 0.0 in 2024, then surged by 320.72% to 0.0 in 2025.
- Per Business Quant, the three most recent readings for FDMT's Asset Utilization Ratio are 0.0 (Q3 2025), 0.0 (Q2 2025), and 0.0 (Q1 2025).